Results 221 to 230 of about 87,772 (336)
Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts+8 more
wiley +1 more source
Secure gray image sharing framework with adaptive key generation using image digest. [PDF]
Nithya C+7 more
europepmc +1 more source
A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira+14 more
wiley +1 more source
Acral melanoma: Molecular subtyping as a gateway to precision medicine. [PDF]
Dika E, Magnaterra E.
europepmc +1 more source
The algebraic structure of the set of enciphering trans formations of a pure cipher is analysed. An alternative definition of pure ciphers is given and necessary and sufficient conditions for the product of two pure ciphers to be pure is found.
openaire +1 more source
A Block-Cipher Mode of Operation for Parallelizable Message Authentication
John Black, Phillip Rogaway
openalex +1 more source
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga+8 more
wiley +1 more source
Image encryption scheme based on thorp shuffle and pseudo dequeue. [PDF]
Geng S, Guo D, Zhang X, Wang Y, Niu Y.
europepmc +1 more source
We investigated whether hypomethylating agents (HMAs) used in myeloid malignancies induce somatic retrotransposition. Our findings indicate that HMA treatment increases L1‐encoded protein expression but does not lead to detectable de novo retrotransposition events in either patient samples or cell lines.
Šárka Pavlová+14 more
wiley +1 more source
Quantum Stream Cipher Based on Holevo-Yuen Theory: Part II. [PDF]
Hirota O, Sohma M.
europepmc +1 more source